Cannabidiol (CBD) is a non-psychoactive compound found in the cannabis plant

Cannabidiol (CBD) is extracted from the cannabis plant

(CSE: PREV, OTCQB: PRVCF) is establishing a new paradigm in cannabinoid drug delivery, says an article in NetworkNewsWire.

Cannabidiol (CBD) is a non-psychoactive compound found in the cannabis plant and is now widely used to treat chronic pain, multiple sclerosis and other conditions.

Some evidence even suggests it can prevent symptoms of Alzheimer’s and appears to promote the death of cancer cells.

Driven by a growing need for pain mitigation and increased awareness of potential health benefits, the global market for CBD is growing at a 39% compound annual growth rate, the report says.

Smallcap health sciences group (CSE: PREV, OTCQB: PRVCF) is "engineering a unique Sol-gel nose-to-brain delivery platform to provide direct, controlled pharmacological drug release".

Many large Canadian firms may find PreveCeutical’s platform superior to current dosing techniques, it added.

These include Canopy Growth Corp (TSX: WEED), Inc. (TSX: APH) and Isodiol International Inc (CSE: ISOL).

PreveCeutical currently has five R&D (research and development) programs, including dual gene therapy for curative and prevention therapies for diabetes and obesity; a Sol-gel platform for nose-to-brain delivery of medical compounds including cannabinoids; Nature Identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).